87
Participants
Start Date
August 13, 2018
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
ipatasertib
Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
Atezolizumab
Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
Royal Marsden Hospital NHS Foundation Trust, Sutton
Hoffmann-La Roche
INDUSTRY
Institute of Cancer Research, United Kingdom
OTHER